✦ LIBER ✦

A feasibility study of roquinimex (Linomide) and alpha interferon in patients with advanced malignant melanoma or renal carcinoma

✍ Scribed by Mackean, MJ; Kerr, D; Lesko, M; Svedberg, A; Hansson, F; Jodrell, D; Cassidy, J

Book ID: 109838703
Publisher: Nature Publishing Group
Year: 1998
Tongue: English
Weight: 666 KB
Volume: 78
Category: Article
ISSN: 0007-0920
DOI: 10.1038/bjc.1998.732

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Role of recombinant interferon alpha2and

Role of recombinant interferon alpha2and cimetidine in patients with advanced malignant melanoma

✍ Tariq I. Mughal; William A. Robinson; M. Roy Thomas; Robert Spiegel 📂 Article 📅 1988 🏛 Springer-Verlag 🌐 English ⚖ 190 KB

EORTC (30885) randomised phase III study

EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma

✍ De Mulder, PHM; Oosterhof, G; Bouffioux, C; van Oosterom, AT; Vermeylen, K; Sylv 📂 Article 📅 1995 🏛 Nature Publishing Group 🌐 English ⚖ 982 KB

Phase II study of etoposide and alpha-in

Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma

✍ Jaffer A. Ajani; James L. Abbruzzese; Avi B. Markowitz; Yehuda Z. Patt; Karen Da 📂 Article 📅 1993 🏛 Springer US 🌐 English ⚖ 201 KB

Cine MRI of swallowing in patients with

Cine MRI of swallowing in patients with advanced oral or oropharyngeal carcinoma: a feasibility study

✍ Anne Marijn Kreeft; Coen R. N. Rasch; Sara H. Muller; Frank A. Pameijer; Eeke Ha 📂 Article 📅 2012 🏛 Springer-Verlag 🌐 English ⚖ 435 KB

A phase I study of recombinant human int

A phase I study of recombinant human interleukin-2 and alpha-interferon-2a in patients with renal cell cancer, colorectal cancer, and malignant melanoma

✍ A. Mittelman; M. Huberman; C. Puccio; B. Fallon; J. Tessitore; S. Savona; R. Eyr 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 662 KB

Preclinical data suggest synergy of interleukin-2 (IL-2) combined with alphainterferon (IFN). In addition, toxicities of IL-2 may be decreased by intermittent continuous infusion. The purpose of this trial was to determine the maximum tolerated dose (MTD) of recombinant IL-2 combined with alpha-IFN

Subcutaneous administration of interleuk

Subcutaneous administration of interleukin 2 and interferon-alpha-2b in advanced renal cell carcinoma: a confirmatory study

✍ Facendola, G; Locatelli, MC; Pizzocaro, G; Piva, L; Pegoraro, C; Pallavicini, EB 📂 Article 📅 1995 🏛 Nature Publishing Group 🌐 English ⚖ 891 KB